Surge in RSV Cases Threatens Infants as Health Officials Urge Vaccination

A significant increase in cases of respiratory syncytial virus (RSV) is impacting the United States, particularly affecting infants and toddlers. Recent data indicates a rise in hospital admissions linked to RSV as the country enters the fall and winter respiratory virus season. This period typically sees a surge in illnesses such as COVID-19 and influenza, but RSV poses unique risks to the youngest members of the population.

According to data from the U.S. Centers for Disease Control and Prevention (CDC) and reported by PopHIVE, a project led by Yale School of Public Health, approximately 1.2% of emergency room visits among infants under one year old were due to RSV for the week ending October 11, 2023. This figure marks a notable increase from 0.4% a month earlier, signaling the onset of what experts describe as an “RSV wave.”

Health officials warn that RSV, which spreads through respiratory droplets and contaminated surfaces, can lead to severe respiratory issues, including pneumonia and bronchiolitis. The California Department of Public Health has highlighted that 2% to 3% of young infants are hospitalized annually due to RSV, often requiring treatments like oxygen or intravenous fluids. Notably, many hospitalized infants were previously healthy before contracting the virus, as indicated in a study published in the journal Pediatrics.

Vaccination Recommendations for Vulnerable Populations

In response to the rising threat, health experts are emphasizing the importance of vaccination. The Los Angeles County Department of Public Health has urged individuals, especially pregnant women, to consider immunization against RSV. Vaccination is recommended for pregnant women between 32 and 36 weeks of gestation, which is roughly one to two months before their expected delivery date.

Dr. Regina Chinsio-Kwong, the Orange County health officer, stated, “Now is exactly the time to get vaccinated if you haven’t already — especially before respiratory virus activity potentially increases later.” The CDC advises vaccinations for older adults, specifically those aged 75 and over, and individuals aged 50 to 74 with underlying health conditions such as diabetes or heart disease.

Currently, three RSV vaccines are available: Moderna’s mResvia, Pfizer’s Abrysvo, and GSK’s Arexvy. While all three can be administered to older adults, only the Pfizer vaccine is approved for pregnant women. Infants can also receive monoclonal antibodies, which function similarly to vaccines, to help protect them against RSV.

Current State of Respiratory Illnesses

The overall activity of respiratory illnesses in California is classified as “very low,” according to state health officials. Nevertheless, the California Department of Public Health noted that Santa Clara County is already observing “medium” levels of RSV in wastewater samples from cities like San José and Palo Alto.

Despite the current low levels of respiratory illnesses, health officials are preparing for a potential increase in RSV, flu, and COVID-19 cases. Vaccination efforts for COVID-19 and flu are also ongoing. The CDC recommends that individuals aged 65 and older, babies aged 6 months to 23 months, and others with specific health risks receive vaccinations for these viruses.

The recent rollout of COVID-19 vaccinations has faced challenges, including confusion regarding eligibility and access. However, recent clarifications have improved access, with pharmacists now able to independently administer COVID-19 vaccinations, according to Dr. Erica Pan, director of California’s Department of Public Health.

With the overlap of RSV, flu, and COVID-19 seasons, public health officials are advocating for comprehensive vaccination strategies to mitigate the impact of these respiratory viruses. Receiving all eligible vaccinations during the same healthcare visit is recommended as best practice to ensure maximum protection against these illnesses.